Editorial commentaries

617 Mortality studies for multiple sclerosis: still a useful tool to analyse long-term outcome
P Ragonese

618 Survival in multiple sclerosis: things have changed
N Gryten

619 A step forward towards personalised immunosuppressive therapy in neuromyelitis optica spectrum disorder
S-H Kim, H J Kim

620 Geographical differences in preventative therapies for neuromyelitis optica spectrum disorder
M Mori, A Uzawa, S Kawabara

Multiple sclerosis

621 Survival and cause of death in multiple sclerosis: a 60-year-longitudinal population-based study
H M B Lunde, J Assmass, K-M Myhr, L Be, N Gryten

626 Excess mortality among patients with multiple sclerosis in Denmark has dropped significantly over the past six decades: a population based study
N Koch-Henriksen, B Laurien, E Stenager, M Magvary

632 Incidence and prevalence of NMOSD in Australia and New Zealand
W Bukhari, K M Prain, P Waters, M Woodhall, C M O’Gorman, L Clarke, R A Silvestrini

Neuro-inflammation

639 Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response

Movement disorders

648 Stability of mild cognitive impairment in newly diagnosed Parkinson’s disease
R A Lawson, A J Yarnall, G W Duncan, D P Breen, T K Khoo, C H Williams-Gray, R A Barker, D J Burn, On behalf of the ICICLE-PD study group

653 Longitudinal assessment of excessive daytime sleepiness in early Parkinson’s disease
A W Amara, L M Chakhtine, C Caspell-Garcia, J D Long, C Coffey, B Höög, A Vidovic, A Iranzo, G Mayer, N Foldvary-Schaefer, R Postuma, W Oertel, S Lasch, K Marek, T Simuni, the Parkinson’s Progression Markers Initiative

MORE CONTENTS ▶
Cerebrovascular disease

663 Surgical clipping or endovascular coiling for unruptured intracranial aneurysms: a pragmatic randomised trial

669 Prevalence, risk factors and consequences of cerebral small vessel diseases: data from three Asian countries
S Hilal, V Mok, Y C Youn, A Wong, M K Ikram, C L-H Chen

Neurodegeneration

675 Examining the language and behavioural profile in FTD and ALS-FTD
J A Saxon, J C Thompson, M Jones, J M Harris, A M T Richardson, T Langheinrich, D Neary, D M A Mann, J S Snowden

Neurogenetics

681 Truncating mutations in SPAST patients are associated with a high rate of psychiatric comorbidities in hereditary spastic paraplegia
V Chelbani, A Tucci, D S Lynch, J M Pelke, L Santos, H Jonvik, S Groppa, N W Wood, H Houlden

General neurology

688 Clinical evoked potentials in neurology: a review of techniques and indications
A M Lascano, P H Lalive, M Hardmeier, P Fuhr, M Seeck

Neuropsychiatry

697 Neuropsychiatric syndromes of multiple sclerosis
R Murphy, S O’Donoghue, T Counihan, C McDonald, P A Calabresi, M A S Ahmed, A Kaplin, B Hallahan

Cranial neuropathies

709 Hypoglossal myokymia presenting as paroxysmal dysarthria following head and neck radiotherapy
T Geraldes, M Alemany, A Lozano, R Velasco

PostScript

711 Letter

Electronic pages
e1 BNFA Abstracts